Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix (TSXV:HEM) closes $2,500,000 convertible debenture

John Ballem  June 11, 2021

Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture

Newsfile June 11, 2021

Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record

Newsfile May 31, 2021

Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update

Newsfile May 29, 2021

Hemostemix to Present at the Emerging Growth Conference

Newsfile May 25, 2021

Hemostemix Announces Closing of Unit Private Placement

Newsfile May 10, 2021

Hemostemix Announces Warrant Repricing and Extension

Newsfile May 6, 2021

Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis

Newsfile April 30, 2021

Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering

Newsfile April 26, 2021

Hemostemix (TSXV:HEM) announces completion of Phase II clinical trial subject follow up

Simon Druker  April 23, 2021

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list

Newsfile April 23, 2021

Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates

Newsfile April 9, 2021

Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.

Newsfile April 8, 2021

Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities

Newsfile March 18, 2021

Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval

Newsfile February 11, 2021

Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced

Newsfile January 28, 2021

Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada

Newsfile January 22, 2021

Hemostemix Announces Grant of Stock Options

Newsfile January 4, 2021

Hemostemix Announces Closing of Unit Private Placement

Newsfile December 31, 2020

Hemostemix (TSXV:HEM) soars on placement’s price protection

Elise Kelly December 29, 2020